查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1975007

全球HER2乳癌筛检市场规模、份额、趋势和成长分析报告（2026-2034年）

Global HER2 Breast Cancer Test Market Size, Share, Trends & Growth Analysis Report 2026-2034
出版日期: | 出版商: Value Market Research | 英文 112 Pages | 商品交期: 最快1-2个工作天内

价格
简介目录

预计 HER2乳癌筛检市场将从 2025 年的 4.3396 亿美元成长到 2034 年的 7.8185 亿美元，2026 年至 2034 年的复合年增长率为 6.76%。

由于全球乳癌发生率不断上升以及早期诊断的重要性日益凸显，全球HER2乳癌检测市场正显着扩张。 HER2检测在製定标靶治疗策略方面发挥至关重要的作用，尤其对于可能受益于HER2标靶治疗的患者。免疫组化和现场杂合反应等先进诊断技术的日益普及进一步推动了市场需求。医疗机构越来越重视精准诊断，以提高存活率和治疗效果。

市场成长主要得益于筛检项目的扩展、检查室基础设施的改善以及患者对基因和生物标记检测认知度的提高。 HER2标靶治疗的进展进一步增加了对准确可靠检测解决方案的需求。政府对癌症研究的支持以及诊断检测的报销政策也促进了检测技术的广泛应用。此外，技术创新正在提升临床检查室的检测准确性、缩短检测週期并提高自动化程度。

由于分子诊断和数位病理学的进步，HER2乳癌检测市场预计将进一步成长。将人工智慧融入诊断流程可望进一步提高准确性和效率。在新兴市场，随着医疗保健服务的改善，预计检测的普及率将进一步提高。随着个人化医疗不断影响癌症治疗，HER2检测仍将是全球乳癌管理策略的关键组成部分。

目录

第一章：引言

第二章执行摘要

第三章 市场变数、趋势与框架

  • 市场谱系展望
  • 渗透率和成长前景分析
  • 价值链分析
  • 法律规范
    • 标准与合规性
    • 监管影响分析
  • 市场动态
    • 市场驱动因素
    • 市场限制因素
    • 市场机会
    • 市场挑战
  • 波特五力分析
  • PESTLE分析

第四章：全球HER2乳癌检测市场：依检测类型划分

  • 市场分析、洞察与预测
  • 免疫组织化学（IHC）
  • 萤光/显色位点杂合反应（FISH/CISH）

第五章：全球HER2乳癌筛检市场：依最终用户划分

  • 市场分析、洞察与预测
  • 医院
  • 诊断检查室
  • 其他的

第六章：全球HER2乳癌检测市场：依地区划分

  • 区域分析
  • 北美市场分析、洞察与预测
    • 我们
    • 加拿大
    • 墨西哥
  • 欧洲市场分析、洞察与预测
    • 英国
    • 法国
    • 德国
    • 义大利
    • 俄罗斯
    • 其他欧洲国家
  • 亚太市场分析、洞察与预测
    • 印度
    • 日本
    • 韩国
    • 澳洲
    • 东南亚
    • 其他亚太国家
  • 拉丁美洲市场分析、洞察与预测
    • 巴西
    • 阿根廷
    • 秘鲁
    • 智利
    • 其他拉丁美洲国家
  • 中东和非洲市场分析、洞察与预测
    • 沙乌地阿拉伯
    • UAE
    • 以色列
    • 南非
    • 其他中东和非洲国家

第七章 竞争情势

  • 最新趋势
  • 公司分类
  • 供应链和销售管道合作伙伴（根据现有资讯）
  • 市场占有率和市场定位分析（基于现有资讯）
  • 供应商情况（基于现有资讯）
  • 策略规划

第八章：公司简介

  • 主要公司的市占率分析
  • 公司简介
    • Abbott Molecular Inc
    • Biogenex Laboratories Inc
    • Leica Biosystems
    • Roche
    • Agilent Technologies
    • Mylab Discovery Solutions Pvt. Ltd
    • Jiangsu HengRui Medicine Co.Ltd
    • Shanghai Henlius Biotech
    • Merus NV
    • GeneQuantum
简介目录
Product Code: VMR112111511

The HER2 Breast Cancer Test Market size is expected to reach USD 781.85 Million in 2034 from USD 433.96 Million (2025) growing at a CAGR of 6.76% during 2026-2034.

The Global HER2 Breast Cancer Test Market is expanding significantly due to the growing incidence of breast cancer worldwide and the rising importance of early diagnosis. HER2 testing plays a critical role in determining targeted treatment strategies, particularly for patients who may benefit from HER2-directed therapies. Increasing adoption of advanced diagnostic technologies such as immunohistochemistry and in situ hybridization is strengthening market demand. Healthcare providers are increasingly emphasizing precision diagnostics to improve survival rates and treatment effectiveness.

Market growth is driven by the expansion of screening programs, improved laboratory infrastructure, and rising awareness among patients about genetic and biomarker testing. Pharmaceutical advancements in HER2-targeted therapies are further increasing the need for accurate and reliable testing solutions. Government support for cancer research and reimbursement policies for diagnostic testing are also encouraging broader adoption. Additionally, technological innovations are enhancing test accuracy, turnaround time, and automation in clinical laboratories.

In the future, the HER2 Breast Cancer Test Market is expected to benefit from advancements in molecular diagnostics and digital pathology. The integration of artificial intelligence in diagnostic workflows may further improve accuracy and efficiency. Emerging markets are likely to witness increased testing adoption due to improving healthcare access. As personalized medicine continues to shape oncology treatment, HER2 testing will remain a critical component of breast cancer management strategies worldwide.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Test Type

  • Immunohistochemistry (IHC)
  • Fluorescence/Chromogenic In Situ Hybridization (FISH/CISH)

By End-user

  • Hospitals
  • Diagnostic Laboratories
  • Others

COMPANIES PROFILED

  • Abbott Molecular Inc, Biogenex Laboratories Inc, Leica Biosystems, Roche, Agilent Technologies, Mylab Discovery Solutions Pvt Ltd, Jiangsu HengRui Medicine Co, Ltd, Shanghai Henlius Biotech, Merus NV, GeneQuantum
  • We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

  • 1.1. Market Segmentation & Scope
  • 1.2. Market Definition
  • 1.3. Information Procurement
    • 1.3.1 Information Analysis
    • 1.3.2 Market Formulation & Data Visualization
    • 1.3.3 Data Validation & Publishing
  • 1.4. Research Scope and Assumptions
    • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

  • 2.1. Market Snapshot
  • 2.2. Segmental Outlook
  • 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

  • 3.1. Market Lineage Outlook
  • 3.2. Penetration & Growth Prospect Mapping
  • 3.3. Value Chain Analysis
  • 3.4. Regulatory Framework
    • 3.4.1 Standards & Compliance
    • 3.4.2 Regulatory Impact Analysis
  • 3.5. Market Dynamics
    • 3.5.1 Market Drivers
    • 3.5.2 Market Restraints
    • 3.5.3 Market Opportunities
    • 3.5.4 Market Challenges
  • 3.6. Porter's Five Forces Analysis
  • 3.7. PESTLE Analysis

Chapter 4. GLOBAL HER2 BREAST CANCER TEST MARKET: BY TEST TYPE 2022-2034 (USD MN)

  • 4.1. Market Analysis, Insights and Forecast Test Type
  • 4.2. Immunohistochemistry (IHC) Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.3. Fluorescence/Chromogenic In Situ Hybridization (FISH/CISH) Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL HER2 BREAST CANCER TEST MARKET: BY END-USER 2022-2034 (USD MN)

  • 5.1. Market Analysis, Insights and Forecast End-user
  • 5.2. Hospitals Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 5.3. Diagnostic Laboratories Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 5.4. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL HER2 BREAST CANCER TEST MARKET: BY REGION 2022-2034(USD MN)

  • 6.1. Regional Outlook
  • 6.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 6.2.1 By Test Type
    • 6.2.2 By End-user
    • 6.2.3 United States
    • 6.2.4 Canada
    • 6.2.5 Mexico
  • 6.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 6.3.1 By Test Type
    • 6.3.2 By End-user
    • 6.3.3 United Kingdom
    • 6.3.4 France
    • 6.3.5 Germany
    • 6.3.6 Italy
    • 6.3.7 Russia
    • 6.3.8 Rest Of Europe
  • 6.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 6.4.1 By Test Type
    • 6.4.2 By End-user
    • 6.4.3 India
    • 6.4.4 Japan
    • 6.4.5 South Korea
    • 6.4.6 Australia
    • 6.4.7 South East Asia
    • 6.4.8 Rest Of Asia Pacific
  • 6.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 6.5.1 By Test Type
    • 6.5.2 By End-user
    • 6.5.3 Brazil
    • 6.5.4 Argentina
    • 6.5.5 Peru
    • 6.5.6 Chile
    • 6.5.7 South East Asia
    • 6.5.8 Rest of Latin America
  • 6.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 6.6.1 By Test Type
    • 6.6.2 By End-user
    • 6.6.3 Saudi Arabia
    • 6.6.4 UAE
    • 6.6.5 Israel
    • 6.6.6 South Africa
    • 6.6.7 Rest of the Middle East And Africa

Chapter 7. COMPETITIVE LANDSCAPE

  • 7.1. Recent Developments
  • 7.2. Company Categorization
  • 7.3. Supply Chain & Channel Partners (based on availability)
  • 7.4. Market Share & Positioning Analysis (based on availability)
  • 7.5. Vendor Landscape (based on availability)
  • 7.6. Strategy Mapping

Chapter 8. COMPANY PROFILES OF GLOBAL HER2 BREAST CANCER TEST INDUSTRY

  • 8.1. Top Companies Market Share Analysis
  • 8.2. Company Profiles
    • 8.2.1 Abbott Molecular Inc
    • 8.2.2 Biogenex Laboratories Inc
    • 8.2.3 Leica Biosystems
    • 8.2.4 Roche
    • 8.2.5 Agilent Technologies
    • 8.2.6 Mylab Discovery Solutions Pvt. Ltd
    • 8.2.7 Jiangsu HengRui Medicine Co.Ltd
    • 8.2.8 Shanghai Henlius Biotech
    • 8.2.9 Merus N.V
    • 8.2.10 GeneQuantum